Gastrointestinal Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gastrointestinal Therapeutics Market Trends and Insights

Rising Burden of Digestive Disorders

As countries increasingly adopt Western dietary patterns, the global incidence of inflammatory bowel disease (IBD) and functional bowel conditions is on the rise. On January 1, 2024, New Zealand reported an IBD prevalence of 671 cases per 100,000 residents.^{[1]The Lancet Editorial Team, “Global Burden of Digestive Diseases,” TheLancet.com} Meanwhile, projections indicate that by 2050, India could see numbers soaring to 456,921 patients.^{[2]The Lancet Editorial Team, “Global Burden of Digestive Diseases,” TheLancet.com} In sub-Saharan Africa, the limited specialist capacity, with fewer than 2 gastroenterologists per 100,000 people, hampers the uptake of biologics. In response, payers are experimenting with nurse-led infusion models, achieving a 40% reduction in per-patient costs without compromising safety. Consequently, while competition from biosimilars has moderated prices, the volume growth remains robust.

Uptake of Next-Generation Biologics & Biosimilars

By Q4 2025, biosimilars accounted for 45% of new biologic initiations in Europe, compared with 22% in the United States. Amgen’s adalimumab biosimilar achieved an 18% share of Humira’s U.S. market volume within 12 months of its 2023 launch. Originator companies are mitigating market erosion through differentiated assets, with AbbVie’s Skyrizi and Rinvoq collectively generating USD 13 billion in 2025, offsetting a 60% decline in Humira sales. Rapid escalation protocols now transition patients to advanced treatments within 18 months of diagnosis, halving the 2020 interval and improving hospitalization outcomes.

Smart-Pill & Sensor Delivery Growth

In August 2024, the FDA approved Medtronic’s PillSense, an ingestible sensor enabling real-time gastric pH tracking to optimize PPI dosing. Subsequently, the PillCam Genius, which utilizes AI for capsule endoscopy and delivers 94% lesion sensitivity, received approval in November 2024.^{[3]Medtronic, “PillCam Genius Press Release,” Medtronic.com} To address the 40% non-compliance rate in ulcerative colitis, Japan introduced a fast-tracked digital mesalamine platform with integrated adherence sensors. With unit costs now below USD 50, these disposables have become economically viable for chronic monitoring. 

Commercialization of Live Microbiome Therapies

The FDA-approved VOWST for Clostridioides difficile infection prevention validates live biotherapeutic modalities and attracted a USD 175 million acquisition by Nestlé Health Science. Phase 1b data for SER-155 point to broader applications in immunocompromised patients, and multiple academic consortia are mapping strain-specific gene clusters to optimize efficacy. Early commercial success spurs venture funding for start-ups developing targeted consortia therapies for ulcerative colitis and hepatic encephalopathy. In 2024, Rebyota and Vowst became the first FDA-approved live biotherapeutics for recurrent C. difficile, establishing a new regulatory pathway. Dedicated microbiome research centers are scaling up, with India’s AIG Hospitals launching a national hub in January 2026 to accelerate gut-based therapeutic development. Lower development costs and favorable safety profiles are attracting venture capital, expediting market entry.

High Biologic Costs

Annual biologic treatment can exceed USD 50,000, straining public and private payers that increasingly impose prior-authorization hurdles. Value-based contracts tie reimbursement to real-world outcomes, compelling manufacturers to fund post-marketing studies. Specialty pharmacies consolidate to negotiate steeper discounts, eroding gross margins yet expanding patient reach through copay-assistance programs. Emerging-market governments explore pooled procurement to lower unit prices, but constrained budgets delay the uptake of biologics compared with small-molecule alternatives. Although biosimilars promise relief, originators often counter with life-cycle management strategies, such as high-concentration formulations, thereby prolonging price rigidity.  

Limited Specialist Availability in Emerging Nations

A projected shortfall of 1,630 gastroenterologists in the United States by 2025 mirrors shortages across Asia-Pacific and Latin America, where rural counties lack any GI specialists. Tele-endoscopy hubs and AI-assisted capsule-imaging interpretation mitigate access gaps but depend on broadband penetration and clinician training. Pharmaceutical firms partner with medical societies to expand fellowship slots, yet the pipeline lags behind the growth in demand. Private-equity-funded clinic chains are scaling endoscopy services in India and Brazil but face regulatory scrutiny over care quality. Persistent workforce deficits slow diagnosis and treatment initiation, tempering near-term sales potential for advanced therapies in underserved regions.  

Segment Analysis

By Drug Class: Microbiome Agents Outpace Mature Categories

Proton pump inhibitors remained the revenue anchor in 2025, holding 23.78% gastrointestinal therapeutics market share, underpinned by widespread management of gastroesophageal reflux disease and ulcer prophylaxis. Branded PPIs still command premiums in hospital formularies where rapid-acting IV formulations are required for acute bleeding, though generics dominate retail channels. The gastrointestinal therapeutics market size attributable to PPIs is expected to plateau as guideline revisions advocate step-down therapy to minimize long-term adverse effects. In parallel, the biologics segment captures incremental spend through anti-TNF agents, IL-12/23 inhibitors, and JAK inhibitors, but faces biosimilar erosion post-2025. Antibiotics, led by rifaximin, retain niche applications in hepatic encephalopathy and small-intestinal bacterial overgrowth, aided by label expansions.  

Microbiome-based therapies comprise the fastest-growing drug class at a 4.33% CAGR, albeit from a low base, benefiting from VOWST’s commercial traction and promising pipelines like SER-155 for immunocompromised hosts. Live biotherapeutic product standardization and scalable anaerobic manufacturing processes cut production costs, narrowing the price gap with conventional biologics. Pharma-food cross-sector collaborations, as exemplified by Nestlé Health Science, infuse diet-adjacent capabilities such as prebiotic adjuncts that enhance colonization. Over the forecast period, the gastrointestinal therapeutics market size for microbiome products is expected to expand as payers accept real-world evidence of relapse reduction in recurrent C. difficile infection.  

Note: Segment shares of all individual segments available upon report purchase

By Disease Indication: IBS Dominates, GI Cancer Accelerates

Inflammatory bowel disease accounted for 29.08% of the gastrointestinal therapeutics market in 2025, generating stable chronic-care revenues through treat-to-target protocols that emphasize mucosal healing. The approach increases biologic dosing frequency and supports the uptake of companion diagnostics, aligning with value-based care metrics. Biosimilar entry for Stelara and Humira suppresses average selling prices yet widens eligible-patient cohorts, softening unit-price erosion. Emerging small-molecule S1P modulators and oral JAK inhibitors may cannibalize anti-TNF share but overall elevate category sales through oral-route convenience.  

Gastrointestinal cancer therapeutics advance at a 4.86% CAGR, driven by precision oncology regimens integrating checkpoint inhibitors with targeted small molecules. AI-enabled colonoscopy improves adenoma detection, facilitating earlier intervention that increases adjuvant-therapy cycles and overall prescriptions. Biomarker-guided therapy for gastric and pancreatic cancers widens patient stratification, and companion diagnostics enhance reimbursement prospects. Though volumes remain smaller than those for reflux or motility disorders, oncology’s premium pricing and continuous line-extension strategies are boosting its revenue trajectory in the gastrointestinal therapeutics market.  

By Route of Administration: Injectables Gain as Oral Dominates

Oral formulations accounted for 62.55% of the gastrointestinal therapeutics market share in 2025, owing to patient convenience and well-established generics across the acid-suppression and motility segments. Yet adherence issues persist in chronic regimens, prompting digital pill-dispensing solutions that track ingestion events and alert caregivers. Oral biologic platforms leveraging permeation enhancers and nanocarriers are in early clinical testing, aiming to capture share from injectables without compromising efficacy.  

Injectables are the fastest-growing route, projected to grow at a 4.65% CAGR through 2031, as large-volume subcutaneous devices enable self-administration previously limited to infusion centers. Hyaluronidase-based co-formulation permits 10-mL subcutaneous dosing, cutting infusion-chair time and hospital overhead. Smart-injector pens offer biometric-based lockout to prevent dosing errors and capture adherence analytics for payer reporting. Although rectal and transdermal routes serve niche populations such as maintenance therapy in distal ulcerative colitis, their market contribution remains marginal within the broader gastrointestinal therapeutics market. 

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Online Pharmacies Disrupt Hospital Dominance

In 2025, hospital pharmacies accounted for 45.21% of distribution revenue, driven by biologics from infusion centers and complex inpatient protocols. Online pharmacies, expanding at a 4.44% CAGR, are utilizing cold-chain logistics and telehealth to deliver specialty drugs directly to patients.

Regulatory approvals for electronic verification of Risk Evaluation and Mitigation Strategy products have expanded the online market. Home nurse infusions are reducing per-dose costs by 30%, increasing price transparency, and challenging traditional hospital markups in the gastrointestinal therapeutics market.

Geography Analysis

North America delivered 38.61% of global revenue in 2025, propelled by high biologic penetration and supportive reimbursement environments despite pronounced specialist shortages across 69.3% of counties. Tele-gastroenterology networks and capsule endoscopy interpretation centers extend reach, but the backlog for elective colonoscopy still stretches clinician capacity. Biosimilar adoption accelerates after updated interchangeability rules, with payer formularies quickly prioritizing cost-saving options.  

Asia-Pacific is the fastest-growing region at a 5.12% CAGR as aging demographics in China and India intersect with government insurance expansion. Urban dietary shifts drive ulcerative colitis and Crohn’s disease incidence, steering investment toward biologics manufacturing facilities in Singapore and South Korea. Meanwhile, Japan’s super-aged society sustains steady demand for PPIs and prokinetics, although strict HTA controls temper price inflation. Digital-health startups capitalize on smartphone penetration to deliver microbiome-tracking apps, integrating seamlessly with hospital EMR systems to guide personalized therapy.  

Europe maintains a balanced outlook, with Germany, the United Kingdom, and France jointly accounting for more than half of regional sales. HTA bodies negotiate aggressive price caps, spurring rapid biosimilar uptake that broadens patient access yet compresses margins. Southern European countries are exploring outcome-based payment models for high-cost biologics, mirroring pilot programs in Scandinavia. In South America and the Middle East & Africa, Brazil and Saudi Arabia spearhead adoption of endoscopy capital equipment and biologics, leveraging public-private partnerships to upgrade hospital infrastructure. Nonetheless, payer fragmentation and import tariffs slow widespread uptake, keeping these regions at an earlier stage of the gastrointestinal therapeutics market development curve.